Douglas Yee MD ABRCC

    Clinical Researchers Showcase Series - June 2017

    Translational Medicine Research:

 View from the Trenches Newsletter

box_top.gif

Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted

only in a lab, to bedside clinical practice or dissemination

to population-based community interventions.

-  Source: NIH -- Read more


from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Douglas Yee, M.D. - ABRCC Investigator

University of Minnesota Medical School

Minneapolis, MN


Dr. Douglas Yee is Professor of Medicine and Pharmacology and the Cancer Center Director at the Masonic Cancer Center, University of Minnesota


Dr. Yee received his MD in 1981 from the University of Chicago Pritzker School of Medicine. He received his internal medicine training and was Chief Medical Resident at the University of North Carolina. His medical oncology training was done at the National Cancer Institute in Bethesda, Maryland. Prior to coming to Minnesota, he held faculty positions at Georgetown University Medical Center and the University of Texas Health Science Center at San Antonio.

Dr. Yee Update on Metastatic Breast Cancer


Among other appointments, Dr. Yee holds the John H. Kersey Chair in Cancer Research. He was previously co-leader of the Women's Cancer Program. Dr Yee specializes in Medical Oncology and Breast Cancer.

•  Director, Masonic Cancer Center (2007-present)
•  Tickle Family Land Grant Chair in Breast Cancer Research (1999-2009)
•  John H. Kersey Chair in Cancer Research (2008-present)
•  Komen for the Cure Scientific Advisory Council (2010)

About the Masonic Cancer Center at the University of Minnesota

The Masonic Cancer Center was founded in 1991. It is part of the University's Academic Health Center, which also includes the Medical School, School of Dentistry, School of Nursing, College of Pharmacy, School of Public Health and College of Veterinary Medicine. The Masonic Cancer Center's research partners include the University’s Stem Cell Institute, Center for Immunology, the Center for Magnetic Resonance Imaging, the Clinical and Translational Science Center and the Physical Sciences in Oncology Center; and its clinical research and treatment partners include University of Minnesota Health Cancer Care, University of Minnesota Medical Center, and University of Minnesota Masonic Children's Hospital. The Masonic Cancer Center, University of Minnesota is designated by the National Cancer Institute as a comprehensive cancer center. The NCI awards this highest-level designation only to institutions that make ongoing, significant advances in cancer research, treatment, and education. Masonic Cancer Center is part of a 47-member group of cancer centers in the United States to hold the comprehensive designation, and the only one in the greater Twin Cities region.. Learn more at: http://www.med.umn.edu/about

box_bottom.gif

About the CONSORTIA MODEL 
for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.

 

To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.


The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website